Top neuroscientists say Biogen's experimental drug for Alzheimer's disease appears to have promise as clinical treatment that slows the disease's attack on the brain -- despite the drug's complicated backstory and conflicting data from two clinical trials. If approved by the FDA, it could become the first drug to attack the dementia-causing disease itself and not just its symptoms.